Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYD dengue vaccine with concomitant or sequential Cervarix in healthy girls aged 9 to 14 years
2019-000994-22Phase 3
- Sponsor
- Sanofi
- Start
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of human papillomavirus type 16 L1 capsid protein antigen and CYD dengue vaccine in dengue fever and human papillomavirus infection (2 arms), sponsored by Sanofi. Primary endpoints: Antibody levels against each Cervarix HPV bivalent antigen after the last dose of Cervarix in previously dengue exposed participants, Non-inferiority of humoral immune response to Cervarix by geometric mean titers and 1 more.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenCYD dengue vaccine
03
Conditions
dengue feverhuman papillomavirus infection
Beyond the preview
Go deeper on 2019-000994-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000994-22.